Aclaris Therapeutics to Present at Upcoming Investor Conferences
September 01 2020 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
management will participate in the following upcoming virtual
investor conferences:
- H.C. Wainwright & Co. 22nd Annual Global Investment
Conference. On Tuesday, September 15, 2020 at 12:30 p.m.
ET, Dr. Neal Walker, the President and CEO of Aclaris, will present
a company overview. Management will be available September 15th
throughout the day for virtual one-on-one meetings with investors
who are registered to attend the conference.
- Cantor Virtual Global Healthcare Conference.
On Thursday, September 17, 2020 at 10:40 a.m. ET., Dr. Walker will
participate in a fireside chat. Management will be available
September 17th throughout the day for virtual one-on-one meetings
with investors who are registered to attend the conference.
A live audio webcast of each presentation may be accessed
through the Events page under the Investors section of Aclaris’
website, www.aclaristx.com. An archived version of each webcast
will be available for 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris
Contact investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024